Pacer Advisors
IMVT icon

Pacer Advisors’s Immunovant IMVT Stock Holding History

Pacer Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-800
Closed -$21.1K – 2619
2024
Q2 		$21.1K Sell
800
-543
-40% -$15.4K ﹤0.01% 3420
2024
Q1 		$43.4K Buy
+1,343
New +$49K ﹤0.01% 3228
2021
Q2 		– Sell
-4,594
Closed -$74K – 1473
2021
Q1 		$74K Buy
4,594
+2,184
+91% +$57.6K ﹤0.01% 1350
2020
Q4 		$111K Buy
+2,410
New +$111K ﹤0.01% 1350

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Pacer Advisors's IMVT Position: Q3 2024 in Review

Pacer Advisors sold out of Immunovant (IMVT) in Q3 2024, closing a stake of 800 shares — an estimated $21.1K sold.

Pacer Advisors first reported a position in IMVT in Q4 2020 and held it in 4 quarters. The position peaked at $111K in Q4 2020. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2024.

  • Pacer Advisors reported no remaining Immunovant position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 800 Immunovant shares in Q3 2024, an estimated $21.1K.
  • Pacer Advisors first reported a position in Immunovant in Q4 2020 and held it in 4 quarters.
  • Pacer Advisors's Immunovant position peaked at $111K in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Immunovant as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.